logo-loader

Northrop Grumman, Orbital ATK, Scorpio Tankers and Neos Therapeutics

Last updated: 10:46 18 Sep 2017 EDT, First published: 02:46 18 Sep 2017 EDT

1505735301_shutterstock_86251318
It was reported Northrop is nearing a deal to buy the rival firm Orbital ATK (NYSE:OA) in a deal valued at around $7.5bn

With US stocks seen higher, several stocks are in play in pre-market deals, including Northrop Grumman Corp (NYSE:NOC)  and aerospace manufacturer Orbital ATK Inc (NYSE:OA).

It was reported  Northrop is nearing a deal to buy the rival firm Orbital ATK (NYSE:OA) in a deal valued at around $7.5bn.

 

The transaction that could be announced as soon as Monday, according to one person , said to be familiar with proceedings.

 

Orbital shares surged  over 19%  to $131.51 after hours. Shares in the regular session added 1.44%.

Elsewhere,Neos Therapeutics Inc ( NASDAQ:  NEOS) shares  shed 4.35% to $8.80 after hours as it reported that it had received the key FDA approval for Adzenys ER. Shares closed 2.22% higher on Friday. In the regular session, shares lost 6.29%  to US$8.62.

Also ion focus on Monday, Steelcase Inc (NYSE:SCS) shares added 1.79%  on Friday ahead of today, where it is expected to post quarterly earnings of $0.23 per share on revenue of $759.83 million after the closing New York bell.

Meanwhile, Scorpio Tankers Inc (NYSE: STNG) shares lost 2,.23% on Friday . It is  expected today to post a quarterly loss at $0.06 per share on revenue of $132.35 million before the opening bell. Shares gained 3.57% in the regular session at US$3.38. 

BenevolentAI advances novel ulcerative colitis treatment through Phase 1a trial

BenevolentAI (OTC:BAIVF) chief scientific officer Dr Anne Phelan joins Proactive's Stephen Gunnion with positive safety data from the Phase 1a, first-in-human, clinical study of BEN-8744 in healthy volunteers. Phelan explained that BEN-8744 is a potent, selective PD10 inhibitor, uniquely...

2 hours, 42 minutes ago